SHYNDEC(SH:600420) Shang Hai Zheng Quan Bao·2025-07-30 17:54Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is publicly transferring 51% equity of its subsidiary, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd., with a base price of RMB 155.192541 million, aiming to optimize resource allocation and improve operational efficiency [2][4]. Group 1: Transaction Overview - The company announced the public transfer of 51% equity of its subsidiary on July 30, 2025, with a base price set at RMB 155.192541 million [2][4]. - The transaction does not constitute a major asset restructuring and is not currently classified as a related party transaction [3][4]. - The transfer aims to enhance the company's strategic focus and asset efficiency, as the subsidiary has been underperforming since 2021 [12]. Group 2: Target Company Information - The target company, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd., was established on November 12, 1999, with a registered capital of RMB 83.29 million [6]. - The company operates in the production and sales of pharmaceuticals, disinfectants, health foods, and other related products [7]. - As of April 30, 2025, the net assets of the target company were valued at RMB 152.0278 million, with a total equity valuation of RMB 304.2991 million, reflecting a 100.16% increase in value [9]. Group 3: Financial Impact and Future Steps - The completion of the equity transfer will result in the subsidiary no longer being included in the company's consolidated financial statements, potentially impacting the company's financial performance for 2025 [12]. - The specific details regarding the buyer and final transaction price remain undetermined, and the company will disclose further information as the transaction progresses [11][12].